{"doi":"10.1056/nejmc2210546","title":"Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants","abstract":"To the Editor: Mounting concern about the long-term efficacy of messenger RNA (mRNA) booster vaccines against coronavirus disease 2019 (Covid-19) 1 has been exacerbated by the recent emergence of the B.1.1.529 (omicron) subvariants BA.2.12.1 and BA.4 and BA.5 (hereafter, BA.4/5) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which have high degrees of immune escape. 2 To address this concern, we used our previously reported pseudotyped lentivirus neutralization assay (see the Supplementary Appendix, available with the full text of this letter at NEJM.org) to examine neutralizing-antibody titers against major SARS-CoV-2 variants in a longitudinal cohort of health care workers from the Ohio State University Wexner Medical Center in Columbus who had received homologous vaccine and booster doses of an mRNA vaccine. A total of 24 participants received the mRNA-1273 vaccine (Moderna), and 22 received the BNT162b2 vaccine (Pfizer-BioNTech). We classified participant samples into three groups according to the timing of booster-dose administration: 1 to 3 months, 4 to 6 months, and 7 to 9 months before the sample was obtained (Table Over the course of the study, 14 participants had a breakthrough infection; 9 cases occurred during the omicron waves.","journal":"New England Journal of Medicine","year":2022,"id":235029,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":87,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9582,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":666619,"name":"Julia N. Faraone","orcid":"0000-0002-3421-4707","position":1,"is_corresponding":false},{"id":278003,"name":"John P. Evans","orcid":"0000-0001-8644-5825","position":2,"is_corresponding":false},{"id":278006,"name":"Yi-Min Zheng","orcid":"0000-0002-0394-9735","position":3,"is_corresponding":false},{"id":375711,"name":"Lianbo Yu","orcid":"0000-0002-2025-2585","position":4,"is_corresponding":false},{"id":235827,"name":"Qin Ma","orcid":"0000-0002-3264-8392","position":5,"is_corresponding":false},{"id":243261,"name":"Claire Carlin","orcid":"0000-0002-8344-0575","position":6,"is_corresponding":false},{"id":278008,"name":"Gerard Lozanski","orcid":"0000-0002-5095-0456","position":7,"is_corresponding":false},{"id":227281,"name":"Linda J. Saif","orcid":"0000-0002-3224-9009","position":8,"is_corresponding":false},{"id":244459,"name":"Eugene M. Oltz","orcid":"0000-0002-2513-7156","position":9,"is_corresponding":false},{"id":629721,"name":"Richard J. Gumina","orcid":"0000-0001-8298-1129","position":10,"is_corresponding":false},{"id":278009,"name":"Shan‐Lu Liu","orcid":"0000-0003-1620-3817","position":11,"is_corresponding":false},{"id":278005,"name":"Panke Qu","orcid":"0000-0002-0222-365X","position":0,"is_corresponding":true}],"reference_count":5,"raw_metadata":null,"created_at":"2026-07-19T00:21:48.116752Z","pmid":"36069925","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}